🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

If you are interested in involving patients & the public in statistical trial methodology or patient-reported outcomes in early phase trials, check out our paper rb.gy/2t9lnt; brilliantly led by PhD student Emily Alger, with DaveChuter@OGcancersupport, Anna Minchom Lee Aiyegbusi & others.

Exciting fully-funded PhD opportunity The ICR in methods research in early phase clinical trials, starting from October 2024. The successful candidate will join an amazing MRC TMRP DTP community of methodologists and innovators! Please share! rb.gy/1dax88 Follow us on Bluesky @ICR-CTSU

Exciting job opportunity for a talented statistician to join us at the Early Phase & Adaptive Trials Group Follow us on Bluesky @ICR-CTSU as a Trials Methodologist! If you enjoy developing and implementing efficient trial methods to impact patients’ lives, come and join us! tinyurl.com/2fpad6z2

Delighted to be involved in this new article by the Methodology for the Development of Innovative Cancer Therapies Taskforce (MDICT). Have a look: rb.gy/ifyw5r

📢#CancerTherapy claiming #TumourAgnostic potential❓ ✔ ORR≥20% in 2/3 of tumour types investigated (≥4) with ≥5 evaluable patients per tumour type 🔓ESMO - Eur. Oncology Tumour-Agnostic Classifier & Screener (ETAC-S) Annals of Oncology Ben Westphalen Vivek Subbiah, MD George Pentheroudakis et al

Superb Congratulations, Haiyan Zheng ! This achievement is so well deserved. I’m really excited to see the valuable methodology contributions you’ll bring to cancer research, and I’m looking forward to continuing our work together on this important journey. 😊

It’s been such a great delight to work with Andrew Kightley, Richard Stevens, Dr. Dawn Richards, PhD and the team, on a toolkit to improve how early phase trial results are communicated to patients and the public. Proud of what we’ve achieved together. rb.gy/z05jzh

We had a great start to #ICTMC2024 this week, with Trial Manager Morgaine Stiles presenting our demographics data collection project DISTINCT, and PhD student Georgiana Synesi, Georgiana Synesi, presenting her work on inclusivity of our bladder cancer and head and neck cancer trials.

Yesterday at #ICTMC2024, principal statistician Jan presented extensions to the SPIRIT and CONSORT guidelines for early phase dose-finding trials (DEFINE).

When you are coming down from the #ICTMC2024 conference and need some more trials methods research highlights then why not download the introductory MRC TMRP DTP led podcast. First full episode drops Tuesday 8th October podcasts.apple.com/gb/podcast/tri…

Innovative trial design meets creative poster in Emily Alger latest work at #ICTMC2024 Follow us on Bluesky @ICR-CTSU

Juanita Lopez, Christina Yap & Richard Mair received an Experimental Medicine Award to build a next generation, glioma modular platform to evaluate the safety & efficacy of genotype matched investigational targeted therapies for malignant #BrainTumours news.cancerresearchuk.org/2024/10/23/3m-…

Excited to have co-designed the efficient 5G platform trial, where we are testing several targeted treatments to help improve the lives of brain cancer patients. Grateful to our funders Science and Innovation at Cancer Research UK and Minderoo Foundation for making this trial possible! ICR_DDU_IIT Follow us on Bluesky @ICR-CTSU CRUK Cambridge Institute

Thank you for the kind invitation to speak at this Trial Methodology Showcase. I enjoyed discussing how innovative methods from cancer trials can inform approaches in other fields, including mental health, and vice versa. Looking forward to exciting synergies ahead!

How about a two sequence (AB/BA) randomised blinded crossover design? PROs: Smaller sample size to achieve the same statistical power. Participants have the opportunity to try both durians & state their individual choice. (Well, I would love to be a participant of such a study!)

Passionate about cancer trials, patient-reported outcomes (PROs) and innovative methods? Join the Early Phase and Adaptive Trials Group at Follow us on Bluesky @ICR-CTSU for an exciting undergraduate summer scholarship in early phase trials and PROs! Deadline: 26/01/25 shorturl.at/1h565

Thank you for the kind invitation to share insights on the value of PROs in phase I dose-finding trials. A fantastic conference in the beautiful city of Barcelona - I’ve learnt so much too! Such a privilege to be part of it!